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1.0 Executive Summary 
 
Although a necessary component of surgery, sutures have been shown to exhibit an 
affinity for microbial adherence and colonization. The sutures offer a conduit for bacteria 
directly into the wound and infection can be difficult to treat post-colonization, even with 
antibiotics that are traditionally very effective. Infections associated with sutures are often 
difficult to resolve and require extended hospitalization, therapy, or additional surgical 
procedures. Drug eluting sutures offer a potential solution to this issue. In order to maximize 
antibiotic delivery, modeling changes in suture size, placement, and concentration could provide 
valuable information for surgeons and manufacturers to better develop and implant sutures, 
reducing the number of surgical site infections (SSIs) and thus morbidity and mortality.  
Using COMSOL software, we first generated both a 2D and a 3D model of 
MONOCRYL plus antibiotic sutures in the skin. Next, we modeled antibiotic-release and 
biodegradation by tracing the distance the drug penetrates into the surrounding tissue while the 
suture and the antibiotic are simultaneously being degraded by the body’s enzymatic processes. 
Finally, we adjusted the distance between adjacent sutures and suture size to ensure that the 
minimum inhibitory concentration (MIC) of triclosan for various bacteria strains was met at the 
wound site, without increasing the difficulty for surgeons to implant the suture.  
In our model, we showed the dispersion of antibiotics into the surrounding tissue over 
time, demonstrating up to what time point the sutures are able to maintain at least the minimum 
effective concentration level of antibiotic. We show that antibiotic levels sufficient enough to 
inhibit bacterial growth can be reached in complex environments, such as the skin. Based on our 
3D model, the maximum spacing between adjacent 4-0 sutures to maintain a MIC for S. aureus 
for 72 hours after suture implantation is 2 mm. Suture spacing for other strains of bacteria can be 
determined through our predictive equations. The duration of antibacterial properties increases as 
the spacing between sutures is decreased, but increasing the initial concentration of triclosan in 
the suture does not significantly increase the duration of antibacterial properties of the suture. 
The suture decreases in volume by 45% seven days after implantation in the skin, indicating 
proper surface erosion and a significant loss in tensile strength after that time. The integrity of 
the suture is necessary to keep the wound closed over the entire healing period, preventing 
bacteria from entering through the open site and entering the tissue and subsequently traveling 
through the bloodstream.  
In this model, we reinforce in vivo and in vitro studies that suggest the effectiveness of 
antibiotic releasing sutures by modeling antibiotic concentrations in the skin following suture 
placement. This model will help surgeons determine the spacing for a variety of commercially 
available sutures, based on the bacterial inhibition properties required, in an effort to reduce the 
number of surgical site infections that occur. By ensuring effective distribution of antibiotic, 
following our developed standards in the surgical suite will reduce the number of surgical site 
infections, significantly reducing costs, morbidity, and mortality from post-operative infections.  
 
2.0 Problem Statement 
 
Surgical site infections (SSIs) can result in significant post- surgical complications, such 
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as preventable infections or sepsis, as well as increased treatment duration and cost. Sutures 
embedded with antibiotic are currently the strongest method for preventing bacterial growth and 
infection at a wound site. However, if the antibiotic concentration in the skin at the wound site is 
not high enough over the period of time it takes for the wound to heal, the antibiotic provides no 
benefit to the patient and infection is likely to occur. The optimal suture type, suture spacing, and 
suture size must be determined for surgeons to optimize effectiveness of the antibiotic in the 
surgical suite and post-operatively.  
 
3.0 Introduction 
 
3.1 Background 
 
The estimated incidence rate of SSIs is 2.8% in the United States, with significant 
morbidity and mortality as well as increases in patient cost and duration of hospital stay (1). 
Approximately 750,000 people contract SSIs each year, costing the healthcare industry over one 
billion dollars (1). Recent advances in drug-eluting degradable sutures allow for antibacterial 
release into tissue following implantation, offering a promising solution to reduce the number of 
SSIs. However, it is difficult to determine correct suture spacing and suture size for optimal 
delivery of antibiotic through an in vitro or in vivo model.  
3.2 Literature Review 
 
Infections associated with sutures are often difficult to resolve, require extended 
hospitalization, therapy, or additional surgical procedures. Although a necessary component of 
surgery, sutures have been shown to exhibit an affinity for microbial adherence and colonization 
(2). Sutures can serve as a conduit for bacteria directly into the wound, and infection can be 
difficult to treat post-colonization, even with antibiotics (3). The physical configuration of a 
suture is an important factor in the susceptibility of a wound to infection. Sutures come in two 
configurations, monofilament and multifilament, which may be twisted or braided. With 
comparison to monofilament sutures, multifilament sutures have greater ease of handling and 
provide greater knot security, thereby decreasing the risk of premature suture failure. However, it 
has been found that sutures in a multifilament configuration harbor bacteria between adjacent 
fibers and the fibers allow for bacteria to migrate freely along the suture through capillary action 
(4). This leads to both higher degrees of local inflammation tissue reactions and higher rates of 
wound infection (4, 5). For this reason, monofilament sutures are frequently chosen for wounds 
not incurred within a sterile field.  
Monofilament sutures can be absorbable (biodegradable) or non-absorbable. Absorbable 
sutures confer the advantage that they will degrade as the tissue heals, eliminating follow-up 
with a clinician to remove the sutures and preventing any foreign-body reactions. However, 
unlike non-absorbable sutures, absorbable sutures lose their strength over time, which may 
compromise the wound’s healing process. Efforts have been made to respond to this issue, 
increasing the strength retention over time. MONOCRYL, a monofilament absorbable suture, 
has been shown to retain 20-30% of its initial tensile strength two weeks after implantation yet 
be completely resorbed after three months
 
(6, 7). In locations where tissue healing is rapid, like at 
the skin surface, absorbable sutures are the ideal choice. For these reasons, biodegradable sutures 
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are typically used at wound sites in an effort to limit the number of doctor visits and prevent 
foreign-body reactions.
 
Non-absorbable sutures can elicit foreign body reactions, leading to 
increased inflammation and infection, and must be physically removed from the patient 
following wound healing (8). 
To further prevent bacterial infection, biodegradable sutures can be impregnated with an 
antibiotic. For example, Ethicon’s MONOCRYL Plus sutures (poliglecaprone 25) with triclosan, 
an antibacterial drug, have been shown to prevent bacterial growth in vitro for up to 11 days (3). 
Degradable sutures also confer the advantage that they allow for nearly constant release of 
antibacterial components within the suture. According to Ming, et al. (2007), MONOCRYL Plus 
Antibacterial Sutures are effective in vitro at prohibiting bacterial growth, each species with a 
unique zone of inhibition that depends on the robustness of the strain tested (Figure 1) (3). 
 
 
Figure 1. In vitro efficacy of poliglecaprone 25 suture with triclosan (MONOCRYL plus), adapted from 
Ming et al (2007). Efficacy was determined by the length of the zone of inhibition, i.e. the higher the zone 
of inhibition, the more effective the suture was at preventing bacterial growth in a Petri dish. MRSA: 
methicillin-resistant S. aureus; MRSE: methicillin-resistant S. epidermidis (3). 
 
The pathogens most commonly found in surgical site infections are S. aureus, S. 
epidermidis, along with E. coli and K. pneumoniae. Figure 1 demonstrates that triclosan-eluting 
sutures are effective at inhibiting all of these bacterial strains. Jones et al (2006) determined the 
MICs of triclosan, a broad-spectrum antibiotic, for different strains of bacteria (9). For most 
strains of E. coli, the triclosan MIC is 0.2 mg/L. For S. aureus, the triclosan MIC for the most 
resistant strain is 0.4-0.6 mg/L (9). We use these values as targets for concentrations in the 
wound area and surrounding skin, as they will be necessary to achieve in order to inhibit 
bacterial growth at the suture and wound site.  
Despite the promise of antibiotic releasing biodegradable sutures, it is a necessity that 
these sutures be sewn properly, in both depth and stitch distance, by the surgeon for optimal 
antibiotic delivery to the surgical site (3). Furthermore, the metabolism of triclosan in the skin 
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must be considered to ensure effective antibiotic properties. In the skin, triclosan is metabolized 
into triclosan glucuronide and triclosan sulfate via skin glucuronyltransferases and 
sulfotransferases, respectfully, mostly in the outer root sheath of the hair follicles, sebaceous 
glands, and stratum basale (10). The metabolism
 
of triclosan decreases the amount that can 
potentially reach the wound site, however the rate of degradation is not very significant 
compared to the inhibitory concentration levels that need to be reached.  
We will use Ethicon’s MONOCRYL plus antibiotic as the basis for our model, as it is 
biodegradable monofilament suture containing triclosan and has been shown to be effective 
against the most common SSI pathogens. The software COMSOL will provide a modeling 
platform that will allow us to optimize suture placement, size, and antibiotic concentration 
without performing many experiments in vitro or in vivo. We will model the diffusion of 
antibiotic from MONOCRYL Plus sutures with degradation in the skin to demonstrate the 
optimum suture placement and size at the wound site in order to prevent bacterial infection and 
growth at the wound.  
 
3.3 Problem Schematic 
 
 To model suture placement and antibiotic concentration profiles in the skin following 
surgery, we first developed a two-dimensional model of the suture. The geometry of the model is 
axisymmetric around the wound, and only half of the suture is shown due to symmetry (Figure 
2). The far-right boundary is set to have a concentration of antibiotic equal to zero, as any 
antibiotic at this location of the skin is immediately taken away by the bloodstream.  
 However, this boundary is not consistent in the two-dimensional axi-symmetric model, as 
the surface of the skin does not contain blood vessels and therefore the cT = 0 boundary condition 
on the far right of the 2D model is not accurate at all locations around the axis. A semi-infinite 
boundary condition here, which was also considered, is also not accurate, as the skin is not deep 
enough for a true semi-infinite boundary. Thus, we extended our model to three dimensions, 
which also allowed us to take into effect the diffusion of triclosan from the external portions of 
the suture into the skin (Figure 2). Furthermore, we were able to more accurately represent the 
stitch pattern in the skin using a 3D model, as the pattern is not perfectly circular and there is a 
significant portion of the stitch outside the skin that is not degraded by enzymes. This portion of 
stitch outside of the skin can still contribute to drug elution profiles within the skin. We also 
implemented a partition coefficient between the stitch and the skin, which is not shown on the 
schematic in Figure 2. Triclosan is degraded at a first order rate in the skin.  
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Figure 2. Diagram depicting suture placement (top) and model schematic in 2D (bottom) and 3D (top). 
Purple – Suture (MONOCRYL-PLUS); Yellow – Epidermis  
 
We first used the 2D model to determine whether antibacterial concentrations high 
enough to inhibit bacterial growth can be reached in a timely manner and to show degradation of 
the suture in the skin. Next, we used our 3D model to optimize the distance between adjacent 
sutures for several suture sizes based on antibiotic concentration, helping surgeons to choose the 
best size and stitching pattern to confer bacterial resistance in the wound following surgery.   
 
3.4 Design Objective  
 
 The goals of this report are to model both the dispersion of antibiotics from an implanted 
suture and absorption of suture from the surrounding tissue, as well as optimize the placement of 
sutures of various sizes to identify an ideal elution profile for combating bacterial infection and 
provide surgeons and physicians with guidelines for suture implantation in the surgical suite, 
reducing costs, morbidity, and mortality.   
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4.0 Governing Equation 
 
In our 2D model, we calculated mass transfer in cylindrical coordinates with a first order 
degradation term within the skin. Equation 1 describes the transport of triclosan (CT) in the skin 
and equation 2 describes the transport of triclosan in the suture with changes in time. Equations 3 
and 4 describe the transport of triclosan in the skin and the suture, respectively, in our 3D model 
with the same conditions.  
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The surface erosion of suture is modeled by equation 5: 
 
d r
d t
K
 (Eq. 5) 
 Where K is the surface erosion rate of the suture, 7 m/day and r is the radius of the 
stitch (11).
 
 
The growth of skin to replace degrading suture uses the same erosion rate as the suture 
(Equation 6).  
 (Eq. 6) 
 Where K is the surface erosion rate of the suture, 7 m/day, and r is the stitch radius (11). 
 Equations 5 and 6 were adapted in the model to account for erosion and growth in all 
three dimensions by multiplying each dimension by the vector normal to the suture surface. 
 
As triclosan diffuses through the tissue, it is metabolized. The metabolism of triclosan in 
the epidermis is modeled with Equation 7. 
RskinkCT  (Eq. 7) 
 Where k is the first order reaction coefficient, -3.18944 x 10
-6
 mol/m
3
/s and CT is the 
concentration of triclosan in the skin (10). 
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5.0 Boundary Conditions 
 
2D: On the left-hand boundary, the flux is zero due to two-dimensional axi-symmetry. The 
right-hand boundary has the concentration of antibiotic equal to zero, due to triclosan being 
taken away by the bloodstream. On the top and bottom boundaries, the flux of triclosan is zero 
due to symmetry. 
 
3D: The bottom of the skin has a concentration of zero due to drug being taken away by 
blood flow at the base of the dermis. The left, front, and back sides have a flux of zero due to 
symmetry. The top is set to an open boundary of zero flux. The right side is considered semi-
infinite because it is far away from the suture in the skin, and so has a flux of zero. 
  
6.0 Initial Conditions 
 
The concentration of triclosan in skin before the suture is placed is zero. The suture diameter 
is originally 0.15 mm, corresponding to a size 4-0 suture (3). The initial suture concentration is 
2360 g/m, which we determined using the cross-sectional area of the suture to be 4.612 mol/m3 
(12). These initial conditions are accurate for both 2D and 3D models. 
 
 
7.0 Results and Discussion 
 
 Triclosan diffuses very quickly away from the suture due to the large differences 
(approximately three orders of magnitude) in the diffusivity of triclosan within the suture and in 
the skin (Figure 3A). The 2D model shows that triclosan has its peak concentration between the 
sutures at the wound site, where bacterial colonization is most likely to occur (Figure 3B). The 
MIC desired for E. coli is 6.91 x 10
-4
 mol/m
3
 and the MIC for S. aureus is 2.07 x 10
-3
 mol/m
3
. 
 
   A               B    
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Triclosan concentration profile in 2D at 3 hours, in mol/m
3
. A) Concentration within the 
computational domain. B) Representation of several sutures over a central wound region, where the 
wound is approximated as the centerline between the sutures.  
mol/m3 
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In the 2D model, the concentration reaches its peak at the center of the wound site 1 mm 
between adjacent sutures at approximately 4 hours after suture implantation at a concentration of 
0.045 mol/m
3
, well above the MIC for both E. coli and S. aureus. (Figure 4A).  Within the center 
of the suture, the triclosan concentration is about half of its initial suture concentration after one 
day and drops away to 0 mol/m
3
 rapidly (Figure 4B). It is crucial that the concentration peaks 
within the 24-hour window, as that is when bacterial infection is most likely to occur. After a 
biomaterial has been present for 24 hours, the risk of infection decreases significantly (13). 
 
A       B 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Concentration profile (mol/m
3
) over 48 hours (A) Between sutures at center within the wound 
(B) Within center of suture.  
 
Our 2D model shows that concentrations of triclosan high enough to inhibit bacterial 
growth are reached in the skin surrounding the suture. However, because of the zero 
concentration boundary condition and schematic, the 2D model only accurately represents the 
suture within the skin itself and does not accurately model the skin surface or diffusion of 
triclosan along the external portions of the suture. Hence, we extended our suture model to 3D to 
better encompass the effects of triclosan diffusion from the externally placed suture, as well as 
model the triclosan concentration profile more accurately at the skin surface. Our 3D model 
(Figure 6A) takes into consideration the oval placement of the suture in the skin, as well as the 
effects of diffusion of triclosan along the suture, degradation of the suture in three dimensions 
(Figure 6B), as well as diffusion of triclosan in the skin in three dimensions (Figure 6C and 
Figure 6D).   
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A      B 
 
C      D 
      
Figure 6. A) Concentration profile of triclosan after suture implantation (time t = 0). B) Concentration 
profile after three days. C) Modified scale (0, 3.8E-3 mol/m
3
) to show distribution near suture after three 
days. D) Modified scale (0, 1.8E-3 mol/m
3
) to show distribution of drug in skin after three days. 
 
By evaluating the concentration profile of triclosan in the 3D model, we observed that 
triclosan diffusion along the suture itself contributes to increased antibiotic delivery (Figure 6C). 
Furthermore, we observe a gradient of triclosan, decreasing in concentration further away from 
the wound (Figure 6D). Diffusion from the 3D suture at a point 1 mm between adjacent sutures 
reaches inhibitory concentrations for the first 72 hours after implantation (Figure 7A).  
 
 
 
 
 
 
 
 
 
 
 
 
mol/m3 
mol/m3 mol/m
3 
mol/m3 
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A              B 
 
Figure 7. Concentration profile (mol/m
3
) over 72 hours in 3D model with moving boundary (A) Between 
sutures at center within the wound (B) Within center of suture. 
 
In order for complete antibacterial properties, the location furthest from the suture in the 
wound must reach MIC for an extended period of time. In Figure 7, we show the concentration 
of triclosan within the wound 1 mm from adjacent sutures reaches a maximum concentration 
well above the MIC for S. aureus after 3 hours. The concentration of triclosan in the suture drops 
rapidly, reaching half of the initial concentration after 3 hours and is nearly depleted after 24 
hours in the skin.  
The concentration of triclosan over time both between sutures and within the suture 
(Figure 7B) in the 3D model mirror the concentrations determined by the 2D model at the same 
locations. With the 3D model, we were able to incorporate drug diffusion through both the 
internal and the external portion of the suture (Figure 8).  
 
 
A      B 
 
Figure 8. Degradation of the MONOCRYL suture A) at time t = 0 B) after 3 days in 3D. The suture is 
shrinking in the skin, and some of the triclosan is diffusing into the skin from the external portion of 
suture.  
 
 The 3D model is also more accurate in that the external portion of the suture is not 
degrading with time, as it is not exposed to enzymes within the skin (Figure 8B). To calculate 
degradation of the suture in the 3D skin model, we plotted the total volume of the suture over 7 
days. In this time period, the suture decreases in volume by ~45% (Figure 10).  
mol/m3 
mol/m3 
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Figure 10. Total stitch volume over time. The total volume of the stitch (including both degrading and 
non-degrading portions) decreases over time, approaching the total volume of the stitch only outside the 
skin, which is not degrading. Over seven days, the total volume of the stitch decreases by about 45%. 
 
 The stitch is approaching a final volume that is 50% of the total volume, as one half of 
the stitch is not being degraded by enzymes as it is outside of the skin. Once the portion of the 
stitch inside the skin has degraded fully, the outside portion of the stitch will fall away from the 
wound site. Degradation of the suture allows for improved antibacterial release, reducing the 
amount of antibiotic that must diffuse through the suture to reach the skin. 
 In order to determine which of the parameters used in this model was the most sensitive 
to change, we performed a sensitivity analysis, varying each the diffusivity of the skin, the 
diffusivity of the suture and the initial concentration of antibiotics by up to 10% (Figure 11). 
Changes in initial concentration showed the largest percent change in concentration of antibiotics 
outside the suture after 72 hours. Changes in suture and skin diffusivity showed a much more 
insensitive response in concentration.  
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A 
 
B 
 
C 
 
Figure 11. Sensitivity analysis to a change in drug diffusivity though the skin and suture. The bar with 
zero percent change represents the parameters used in the model (Dskin=4.17e-11 m
2
/s, Dsuture=1.90e-13 
m
2
/s, Initial Concentration 4.612 mol/m
3
). The magnitude of the bars represent the percent change in 
antibiotic concentration just outside the suture 3 days after implantation. A) Sensitivity of concentration 
with respect to skin and suture diffusivity. B) Sensitivity of concentration with respect to suture 
diffusivity and initial concentration. C) Sensitivity of concentration with respect to skin diffusivity and 
initial concentration.  
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 One of the main goals of this study was to determine the effect of suture spacing on the 
concentration profile of triclosan in the skin. The 3D model was run using a variety of distances 
between the sutures to determine beyond which spacing the minimum inhibitory concentration 
would not be reached 3 days after implantation. The concentration profile at a point equidistant 
between adjacent sutures decreases with larger distances, and spacing beyond 6mm no longer 
showing an initial peak and decay pattern. (Figure 12).  
 
 
Figure 12. The effect on suture spacing on the concentration profile of antibiotics midway between the 
stitches, at the wound site.  
 
As infection is most likely to occur in the first 72 hours after surgery, choosing a spacing 
that would be most likely to prevent infection during these critical hours is extremely important. 
Given that the MIC of S. aureus growth is 2.07 x10
-3
 mol/m
3
, our model predicts a maximum 
allowable spacing of 2 mm between sutures should be used during surgery for the standard size 
and triclosan concentration found in MONOCRYL Plus sutures (Figure 12). Given that the MIC 
for preventing E. coli growth is 6.91 x10
-4
 mol/m
3
, our model predicts a maximum allowable 
spacing of 4 mm between sutures should be used during surgery for the standard size and 
triclosan concentration found in MONOCRYL Plus sutures (Figure 13). There is a decay in the 
concentration at the 72 hour mark within the wound site with increasing spacing.  
 
 
 
0.00E+00
5.00E-03
1.00E-02
1.50E-02
2.00E-02
2.50E-02
3.00E-02
3.50E-02
4.00E-02
0 10 20 30 40 50 60 70
C
o
n
c
e
n
tr
a
ti
o
n
 (
m
o
l/
m
3
) 
time (hours) 
1 mm spacing
1.5 mm spacing
2 mm spacing
4 mm spacing
6 mm spacing
8 mm spacing
10 mm spacing
16 
 
Figure 13. The effect of suture spacing on the concentration of triclosan in the center of the wound 
furthest from the 4-0 suture 72 hours after implantation. Horizontal lines indicate MIC concentrations for 
S. aureus (green) and E. coli (orange).  
 
 We repeated these calculations with different sized sutures, in order to cover a broader 
range of wound sizes and shapes. Different sized sutures are used in different scenarios and 
wound types, and we wanted our model to be used for a broad range of situations. Table 1 shows 
our recommended spacing to ensure MIC levels for at least 72 hours for four different suture 
sizes and the two most common bacterial strains.   
 
Table 1. Recommended suture spacing for different sized sutures and different bacterial strains. Each 
bacterial strain has a different minimum inhibitory concentration that must be met at the wound to prevent 
growth. 
 Size 5-0 Size 4-0 Size 3-0 Size 2-0 
E. coli 2 mm 4 mm 6 mm >10 mm 
S. aureus --- 2 mm 4 mm 8 mm 
 
 
 Our model showed that size 5-0 sutures are too small to prevent S. aureus growth, even at 
distances as close as 1 mm between sutures. A higher initial concentration of triclosan would be 
necessary in order to counteract this problem. Size 2-0 sutures are extremely large, and for 
weaker bacterial strains, such as E. coli, the surgeon can be confident that the MIC will be met 
for at least 72 hours, even if the stitches are further apart. However, we did not want to limit the 
surgeons to two bacterial strains that we picked. If a hospital is known to have a common strain 
or perhaps a more resistant strain of bacteria, our predictive equations can demonstrate the exact 
maximum spacing between sutures in order to prevent bacterial infection (Table 2). In Table 2, Y 
represents the MIC that needs to be met for at least 72 hours at the wound site and X represents 
the recommended minimum distance between sutures. 
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Table 2. Equations developed that predict the spacing that must be maintained in order to prevent a given 
minimum inhibitory concentration for different sized sutures. 
 Predictive Equation 
Size 5-0 y = 0.0016x
-1.068 
Size 4-0 y = 0.0039x
-1.081
 
Size 3-0 y = 0.0069x
-1.095
 
Size 2-0 y = 0.0169x
-1.105
 
 
 
 Triclosan coated sutures have been shown to significantly reduce the number of SSIs by 
30% compared to uncoated sutures from the same manufacturer, especially in abdominal surgery 
and clean or clean-contaminated incisions in 3,720 patients (4). We have observed that the MIC 
for S. aureus was reached at the most distant point between sutures for 40 hours with 4 mm 
spacing between sutures. However, at larger suture separation, the MIC is reached for much 
shorter time periods, which may result in decreased effectiveness in antibacterial properties. 
Additionally, implantation of antibiotic-embedded sutures into guinea pigs and mice showed 
reduced bacterial colonization compared to non-antibiotic infused sutures after 48 hours.    
To validate our model, we compared our results to studies modeling diffusion of triclosan 
through sections of cadaver skin. Studies modeling penetration and metabolism of triclosan 
through human and rat epidermis have shown that 24 hours following application of triclosan, 
6.3% of the applied surface dose had penetrated through 200 m skin sections and 25% of the 
dose remained in the skin (10). To compare across different study setups, we plotted the 
concentration of triclosan 200 m away from the suture surface vs. time, normalizing the 
concentration values to the maximum concentration obtained. We see significant overlap at early 
time points between the normalized concentration in the stratum corneum and the diffusion 
profile from our suture model and a very similar peak and decay concentration profile (Figure 
14).  
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Figure 14. Diffusion profile of our 3D model (red) and Moss et al (1999) work on diffusion of triclosan 
through 200 m segments of human stratum corneum (blue). Absolute concentrations are normalized to 
the maximum concentrations that are reached in the stratum corneum to account for the differences 
between diffusion from a suture and from triclosan applied directly to the skin.  
 
Differences at later time points may be due to the fact that the suture begins with a finite 
amount of triclosan, while in the experiment carried out by Moss et al, triclosan remains in high 
quantity on the skin surface throughout the experiment. For this reason, comparing absolute or 
relative values is not feasible due to the different application modes. However, comparing 
solutions as a fraction of their maximum concentration gives insight into the diffusion profile and 
the time needed to reach a maximum concentration at a certain point in the skin. Additionally, In 
vivo studies of MONOCRYL plus sutures subcutaneously implanted along with E. coli and S. 
aureus show a 2 log reduction and 3.4 log reduction in bacterial concentrations when compared 
to un-impregnated sutures of the same material. (3) 
8.0 Conclusions  
 
The 2D model shows that the concentration of triclosan reached at the wound site is high 
enough for inhibition of bacterial growth. The concentration profile at the wound site peaks in 
the first 24 hours. Based on the results of this model, we suggest to surgeons using MONOCRYL 
plus sutures place them with a minimum 2 mm spacing in the skin for effective triclosan elution 
over 72 hours for the standard 4-0 MONOCRYL suture size and antibiotic concentration. In 
addition, we have created a chart based on bacterial strain and suture size that surgeons can use 
as a guide to evaluate the maximum spacing between sutures. We have also created predictive 
equations, based on our model, which surgeons could use to evaluate the spacing between 
sutures when trying to inhibit bacterial growth.  
Our research has vast implications for medicine. Our recommendations may possibly 
change the way that surgeons and physicians add sutures to wounds. We have developed 
guidelines that, if implemented correctly and broadly, can considerably reduce morbidity and 
mortality of infections at the surgical site as well as the costs associated with such infections. 
Our model could also be extended to wounds not incurred during surgery.  
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9.0 Recommendations 
 
Further research could look at sutures along wounds that are not straight incisions. The 
wound site would not necessarily be in the center of the suture, which could affect the 
recommended spacing of the sutures. The stitches could also be modified such that their depth 
into the skin is modified to be deeper or shallower. This would also affect the antibiotic 
concentrations at the wound site and could alter recommendations. Our model does not include 
the knot at the surface of the skin and assumes that the stitches are not continuous – both of 
which may affect antibiotic concentrations and wound closure. The model could also be 
expanded to subcutaneous tissue closure, where the entire suture is embedded in the body and 
modifications would be made to take into account the various tissue microclimates.  
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Appendix A.  
 
Table 3. Properties for modeling triclosan release from the suture in the skin. 
DTriclosan in polyamide 1.12 x 10
-14
 m
2
/s (15) 
DTriclosan in viable epidermis 4.167 x 10
-11
 m
2
/s (16) 
Initial Radius of Suture 7.5 x 10
-5
 m (7, 11, 12)  
Rate Coefficient of triclosan Metabolism 3.81944 x 10
-6
 mol/m
3
/s 
(10) 
Suture Degradation Rate 7 x 10
-6
 m/day (11) 
Partition Coefficient Log Po/w = 4.8 (17) 
Initial triclosan concentration in suture 4.612 mol/m
3
 (12) 
Initial triclosan concentration in skin 0 mol/m
3
 
  
 The rate coefficient of triclosan in the skin was developed from Moss et al. (1999) 
measurements of triclosan glucuronide and triclosan sulfate in human skin after dosing triclosan 
on the surface as a fraction of the original dose. Thus, we assumed a first order degradation rate 
based on the changes in both triclosan glucuronide and triclosan sulfate combined over time. 
Table 3 depicts all parameters used in our model.  
Appendix B.  
 
To solve the algebraic equations, a direct MUMPS solver was used. The fully coupled 
solver was also direct. Time stepping was initially small, but increased at later times, as much of 
the change occurred in the first twenty-four hours, after which steady state was almost always 
achieved. Time stepping was chosen to keep computation time reasonable but still accurately 
demonstrate concentration changes. All tolerances were either calculated automatically or were 
default values in COMSOL. 
In order to simplify the problem and minimize the amount of elements needed, the mesh 
convergence analysis was performed on the 2D boundary between the suture and the skin. 
Triangular elements were used, with a ‘normal’ mesh coarseness in both the suture in the skin 
and variations in the coarseness of the boundary mesh. Figure 15 shows that the mesh converges 
around 12,000 elements for both early and later time points. The analysis was performed by 
tracking the triclosan concentration just outside of the suture at 3 and 24-hour time points, as this 
concentration is likely to be affected by the mesh at the boundary. We chose the 12,000-element 
mark to continue with the rest of the project to ensure that the mesh was fine enough to 
accurately model the transport of the antibiotics through the suture and skin but would not take 
unnecessary computation time.   
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Figure 15. Mesh convergence of concentration just outside the suture, in 2D geometry with moving 
boundary condition and a partition coefficient. Solution appears to converge by 12,000 elements for both 
early time points (3 hours, left) and later time points (24 hours, right).  
 
We performed a mesh convergence on the 3D model by varying the maximum element 
size along the boundary between the skin and the suture. The free tetrahedral elements in the 
mesh were set to ‘normal’ mesh density in the suture and the skin, and the number of elements 
was varied on the suture-skin boundary. Convergence was determined by calculating the 
triclosan concentration at a point just outside of the suture boundary (Figure 17A and 17B). 
According to the mesh profile (Figure 16), the model is accurately depicted with a minimum of 
100,000 elements (Figure 17C). We used 100,000 elements to run the model. This corresponds to 
a maximum element size of 1E-5 m. We did not use an adaptive mesh, which may impact our 
results, given the fact that the skin-suture boundary is changing.  
 
 
Figure 16. Mesh profile for 3D model at converged mesh element size displaying greatest mesh 
concentration at the suture boundary within the skin. Left panel depicts a zoomed out version of the 3D 
mesh, while right panel focuses on the suture boundary where the mesh is the densest.  
 
 
 
A             B 
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Figure 17. Mesh convergence in 3D geometry with moving boundary condition. Mesh convergence was 
calculated by examining the concentration along a line drawn through the center of the suture depth-wise 
into the skin. Mesh elements are concentrated at suture boundary A) At the 24 hour time point, the mesh 
converges around 100,000 elements. B) Zoomed-in view. C) Concentration vs. number of elements at 
point D) just outside of the suture.  
 
As shown in Figure 16 and Figure 17, we reduced discretization error through mesh convergence 
in our model.  
Appendix C. 
 
 To depict multiple stitches in the skin, we generated mirror plots showing changes in 
concentration of triclosan in a realistic image of multiple stitches, as they would appear after 
implementation in the wound (Figure 18).  
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Figure 18. Concentration surface mirror plots for 3D model showing three stitches along a wound site. A) 
At initial time (t=0). B) After 24 hours.  
 
 
 
Figure 19. Mesh inversion that took place at later timepoints (after 120 hours) in both 2D and 3D models 
before correction.  
 
Before correction, both of our 2D and 3D models showed mesh inversion at later timepoints 
(Figure 19). This was corrected in the 3D model to ensure accurate measurements of stitch 
volume after 7 days. All other computation was performed before the mesh began to invert.  
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